• Marinus Pharmaceuticals (NASDAQ:MRNS) saw its shares drop about 65% premarket on Thursday after its late-stage trial of oral ganaxolone for treating seizures associated with tuberous sclerosis complex (TSC) in children and adults failed to meet the primary endpoint.
• While reductions in seizure

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.